Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5969689 | 0.83 | CYP2D6 (0.38) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL8633239 | 0.83 | CYP2D6 (0.38) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL544794 | 0.82 | CYP2D6 (0.46) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL26109316 | 0.82 | CYP2D6 (0.46) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL27410703 | 0.78 | DGAT1 (0.39) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2331892 | 0.77 | CYP2D6 (0.44) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL6776410 | 0.77 | CYP2D6 (0.37) | CYP2D6GRIK1 | |
| SCHEMBL31301962 | 0.77 | CYP2D6 (0.44) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL27394363 | 0.76 | DGAT1 (0.38) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2024581 | 0.76 | GRIK1 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| US-8268318-B2 | Polyalkylene oxides having hindered ester-based biodegradable linkers | ENZON PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20090232833-A1 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| EP-2063709-A2 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY | Enzon Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008034122-A2 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090232833-A1 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS | CES2, PLOD3, FASN | CYP2D6 3616/4885HDAC3 64/4885HDAC1 662/4885 |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | IDO1, IDO2, INMT | CYP2D6 86/4885HDAC3 964/4885HDAC1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.